Carcinoma of unknown primary: Retrospective study about 437 patients treated at Salah Azaiez Institute;Carcinomes de primitif inconnu: Etude rétrospective à propos de 437 patients traités à l'institut Salah Azaiez

Tunisie Medicale

Volumn 91, Issue 3, 2013, Pages 205-208

  Fehri, Rania ^a   Rifi, Hela ^a   Alboueiri, Adel ^a   Malouche, Dhafer ^b   Ayadi, Mouna ^a   Rais, Henda ^a   Mezlini, Amel ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

^b UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Carcinoma; Metastases; Prognosis; Survival; Unknown primary

Indexed keywords

CISPLATIN;

ADENOCARCINOMA; ADRENAL METASTASIS; ADULT; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; FEMALE; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; THORAX RADIOGRAPHY; UNDIFFERENTIATED CARCINOMA;

CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; TUNISIA;

EID: 84877985063     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M. Hepatic metastases from carcinomas of unknown primary site. Experience of the Montpellier Cancer Center. Gastro enterol Clin Biol 2005; 29: 1224-32.
2. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009; 69: 271-8.
3. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12: 1272-80.
4. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer 1986; 57: 120-4.
5. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev 2008; 34: 693- 700.
6. Ben Abdallah M, Zehani S, Ben Ayoub W. North Tunisia Cancers Register: data for 1999-2003. 2nd edition Tunis. 2009.
7. Van De Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands,1984-1992. Eur J Cancer 2002; 38: 409-13.
8. Culine S, Gazagne L, Ychou M et al. Carcinoma of unknown primary. About 100 patients treated in the regional cancer center of Montpellier. Rev Méd lnterne 1998; 19: 713-9.
9. Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg 2007; 194: 833-8.
10. Shaw PH, Adams R, Jordan C, Crosby TD. A Clinical Review of the Investigation and Management of Carcinoma of Unknown Primary in a Single Cancer Network. Clin Oncol 2007; 19: 87-95.
11. Le Cesne A, Le Chevalier T, Caille P et al. Metastases of unknown primary. Study of 302 autopsies. Press Méd 1991; 20: 1369-73.
12. Hainsworth JD, Greco AF. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993; 329: 257-63.
13. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
14. Hamilton CS, Langlands AO. ACUPS (adenocarcinoma of unknown primary site): a clinical and cost benefit analysis. Int J Radiat Oncol Biol Phys 1987; 13: 1497-503.
15. Stewart JF, Tattersall MHN, Woods RL, Fox RM. Unknown primary adenocarcinoma: incidence of over investigation and natural history. Br Med J 1979; 1: 1530-3.
16. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-103.
17. Bugat R, Bataillard A, Lesimple T et al. Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site. Bull Cancer 2002; 89: 869-75.
18. Sporn JR, Greenberg BR. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol 1993; 20: 261-7.
19. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVitaVT, Hellman S, Rosenberg SA, eds, Cancer: principles and practice of oncology, 8th ed. Philadelphia: J.B. Lippincott Co, 2008: 2363-83.
20. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007; 33: 656-63.
21. Culine S, Lortholary A, Voigt JJ et al. A trial of the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI01). J Clin Oncol 2003; 21: 3479-82.
22. Dowell JE, Garrett AM, ShyrY, Johnson DH, Hande KR. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001; 91: 592-7.
23. Hainsworth JD, Spigel DR, Clark BLx, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 2010; 16: 70-5